U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Fallopian Tube Undifferentiated Carcinoma

MedGen UID:
1737970
•Concept ID:
C5418772
•
Neoplastic Process

Definition

The reemergence of fallopian tube undifferentiated carcinoma after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Fallopian Tube Undifferentiated Carcinoma

Professional guidelines

PubMed

Frontline Maintenance Treatment for Ovarian Cancer.
Elyashiv O, Wong YNS, Ledermann JA
Curr Oncol Rep 2021 Jun 14;23(8):97. doi: 10.1007/s11912-021-01088-w. PMID: 34125335Free PMC Article
Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer.
Longoria TC, Tewari KS
Expert Opin Drug Metab Toxicol 2018 May;14(5):543-550. Epub 2018 May 16 doi: 10.1080/17425255.2018.1461838. PMID: 29620474
Management of Fallopian Tube Cancer.
Rai S, Maheshwari A
Rev Recent Clin Trials 2015;10(4):276-81. doi: 10.2174/1574887110666150923112556. PMID: 26411954

Recent clinical studies

Etiology

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib.
Guo M, Shu Y, Chen G, Li J, Li F
Sci Rep 2022 Nov 29;12(1):20601. doi: 10.1038/s41598-022-23726-4. PMID: 36446798Free PMC Article
Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment.
Schoutrop E, Moyano-Galceran L, Lheureux S, Mattsson J, Lehti K, Dahlstrand H, Magalhaes I
Semin Cancer Biol 2022 Nov;86(Pt 3):207-223. Epub 2022 Apr 5 doi: 10.1016/j.semcancer.2022.03.027. PMID: 35395389
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators
Lancet Oncol 2020 May;21(5):699-709. Epub 2020 Apr 16 doi: 10.1016/S1470-2045(20)30142-X. PMID: 32305099
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators
Lancet 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12 doi: 10.1016/S0140-6736(17)32440-6. PMID: 28916367Free PMC Article
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS
Lancet Oncol 2017 Jun;18(6):779-791. Epub 2017 Apr 21 doi: 10.1016/S1470-2045(17)30279-6. PMID: 28438473Free PMC Article

Diagnosis

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib.
Guo M, Shu Y, Chen G, Li J, Li F
Sci Rep 2022 Nov 29;12(1):20601. doi: 10.1038/s41598-022-23726-4. PMID: 36446798Free PMC Article
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Chitiyo VC, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA III, Leiserowitz G, Liu J, Martin L, Matei D, McHale M, McLean K, Miller DS, Percac-Lima S, Remmenga SW, Schorge J, Stewart D, Thaker PH, Vargas R, Hendrickson AW, Werner TL, Zsiros E, Dwyer MA, Hang L
J Natl Compr Canc Netw 2022 Sep;20(9):972-980. doi: 10.6004/jnccn.2022.0047. PMID: 36075393
Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment.
Schoutrop E, Moyano-Galceran L, Lheureux S, Mattsson J, Lehti K, Dahlstrand H, Magalhaes I
Semin Cancer Biol 2022 Nov;86(Pt 3):207-223. Epub 2022 Apr 5 doi: 10.1016/j.semcancer.2022.03.027. PMID: 35395389
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS
Lancet Oncol 2017 Jun;18(6):779-791. Epub 2017 Apr 21 doi: 10.1016/S1470-2045(17)30279-6. PMID: 28438473Free PMC Article
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR
J Clin Oncol 2012 Jun 10;30(17):2039-45. Epub 2012 Apr 23 doi: 10.1200/JCO.2012.42.0505. PMID: 22529265Free PMC Article

Therapy

Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850).
Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, Margariti PA, Chiantera V, Costantini B, Gueli Alletti S, Cosentino F, Scambia G
Int J Gynecol Cancer 2020 Nov;30(11):1657-1664. Epub 2020 Oct 7 doi: 10.1136/ijgc-2020-001640. PMID: 33028623
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators
Lancet Oncol 2020 May;21(5):699-709. Epub 2020 Apr 16 doi: 10.1016/S1470-2045(20)30142-X. PMID: 32305099
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators
Lancet 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12 doi: 10.1016/S0140-6736(17)32440-6. PMID: 28916367Free PMC Article
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS
Lancet Oncol 2017 Jun;18(6):779-791. Epub 2017 Apr 21 doi: 10.1016/S1470-2045(17)30279-6. PMID: 28438473Free PMC Article
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR
J Clin Oncol 2012 Jun 10;30(17):2039-45. Epub 2012 Apr 23 doi: 10.1200/JCO.2012.42.0505. PMID: 22529265Free PMC Article

Prognosis

Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850).
Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, Margariti PA, Chiantera V, Costantini B, Gueli Alletti S, Cosentino F, Scambia G
Int J Gynecol Cancer 2020 Nov;30(11):1657-1664. Epub 2020 Oct 7 doi: 10.1136/ijgc-2020-001640. PMID: 33028623
Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S, van Stein R, Sikorska K, Barton D, Perrin L, Brennan D, Zivanovic O, Mosgaard BJ, Fagotti A, Colombo PE, Sonke G, Driel WJV; OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group
Int J Gynecol Cancer 2020 Jun;30(6):888-892. Epub 2020 Mar 23 doi: 10.1136/ijgc-2020-001231. PMID: 32205449Free PMC Article
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators
Lancet 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12 doi: 10.1016/S0140-6736(17)32440-6. PMID: 28916367Free PMC Article
ReMixT: clone-specific genomic structure estimation in cancer.
McPherson AW, Roth A, Ha G, Chauve C, Steif A, de Souza CPE, Eirew P, Bouchard-Côté A, Aparicio S, Sahinalp SC, Shah SP
Genome Biol 2017 Jul 27;18(1):140. doi: 10.1186/s13059-017-1267-2. PMID: 28750660Free PMC Article
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS
Lancet Oncol 2017 Jun;18(6):779-791. Epub 2017 Apr 21 doi: 10.1016/S1470-2045(17)30279-6. PMID: 28438473Free PMC Article

Clinical prediction guides

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Gilbert L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, Lim PC, Castro CM, Provencher D, Memarzadeh S, Method M, Wang J, Moore KN, O'Malley DM
Gynecol Oncol 2023 Mar;170:241-247. Epub 2023 Feb 1 doi: 10.1016/j.ygyno.2023.01.020. PMID: 36736157
Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850).
Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, Margariti PA, Chiantera V, Costantini B, Gueli Alletti S, Cosentino F, Scambia G
Int J Gynecol Cancer 2020 Nov;30(11):1657-1664. Epub 2020 Oct 7 doi: 10.1136/ijgc-2020-001640. PMID: 33028623
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
O'Malley DM, Matulonis UA, Birrer MJ, Castro CM, Gilbert L, Vergote I, Martin LP, Mantia-Smaldone GM, Martin AG, Bratos R, Penson RT, Malek K, Moore KN
Gynecol Oncol 2020 May;157(2):379-385. Epub 2020 Feb 18 doi: 10.1016/j.ygyno.2020.01.037. PMID: 32081463
ReMixT: clone-specific genomic structure estimation in cancer.
McPherson AW, Roth A, Ha G, Chauve C, Steif A, de Souza CPE, Eirew P, Bouchard-Côté A, Aparicio S, Sahinalp SC, Shah SP
Genome Biol 2017 Jul 27;18(1):140. doi: 10.1186/s13059-017-1267-2. PMID: 28750660Free PMC Article
Clinical Outcomes among Women with Mucinous Adenocarcinoma of the Ovary.
Massad LS, Gao F, Hagemann I, Powell M
Gynecol Obstet Invest 2016;81(5):411-5. Epub 2015 Nov 20 doi: 10.1159/000441791. PMID: 26583769Free PMC Article

Recent systematic reviews

The Efficacy and Safety of Folate Receptor α-Targeted Antibody-Drug Conjugate Therapy in Patients With High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers: A Systematic Review and Meta-Analysis.
Kim ET, Kim JH, Park EY, Song IH, Park HS, Park SY, Lim MC
Cancer Med 2024 Nov;13(21):e70392. doi: 10.1002/cam4.70392. PMID: 39526448Free PMC Article
Evaluation of follow-up strategies for women with epithelial ovarian cancer following completion of primary treatment.
Zachou G, El-Khouly F, Dilley J
Cochrane Database Syst Rev 2023 Aug 31;8(8):CD006119. doi: 10.1002/14651858.CD006119.pub4. PMID: 37650760Free PMC Article
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
Newhouse R, Nelissen E, El-Shakankery KH, Rogozińska E, Bain E, Veiga S, Morrison J
Cochrane Database Syst Rev 2023 Jul 5;7(7):CD006910. doi: 10.1002/14651858.CD006910.pub3. PMID: 37407274Free PMC Article
Occult Tubal Carcinoma After Risk-Reducing Salpingo-oophorectomy: A Systematic Review.
Piedimonte S, Frank C, Laprise C, Quaiattini A, Gotlieb WH
Obstet Gynecol 2020 Mar;135(3):498-508. doi: 10.1097/AOG.0000000000003702. PMID: 32028491
Outcome and Prognostic Impact of Surgical Staging in Serous Tubal Intraepithelial Carcinoma: A Cohort Study and Systematic Review.
Van der Hoeven NMA, Van Wijk K, Bonfrer SE, Beltman JJ, Louwe LA, De Kroon CD, Van Asperen CJ, Gaarenstroom KN
Clin Oncol (R Coll Radiol) 2018 Aug;30(8):463-471. Epub 2018 Apr 22 doi: 10.1016/j.clon.2018.03.036. PMID: 29691126

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...